AUROBINDO PHARMA – USTEKINUMAB BIOSIMILAR PACT TERMINATED

• Agreement Ended: CuraTeQ, Aurobindo Pharma’s wholly-owned subsidiary, has mutually terminated its license agreement with BioFactura, USA, for BFI-751 (ustekinumab biosimilar). • Timeline: The original agreement was signed on 7 July 2023 and has been terminated with effect from 27 December 2025. • Project Details: BFI-751 was planned as a biosimilar to Stelara, with provisions for profit-sharing, global manufacturing rights, and milestone-linked license fees. • Strategic Rationale: Termination is in line with CuraTeQ’s portfolio prioritisation and overall biosimilar strategy. • Financial Impact: The company stated that the termination is not expected to have any material financial impact.